NeuroMetrix (NURO) Competitors $4.40 +0.06 (+1.47%) Closing price 04/17/2025 03:50 PM EasternExtended Trading$4.32 -0.09 (-2.02%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NURO vs. DXR, SPAI, OM, MODD, POCI, FEMY, MDAI, CLGN, COCH, and PYPDShould you be buying NeuroMetrix stock or one of its competitors? The main competitors of NeuroMetrix include Daxor (DXR), Safe Pro Group Inc. Common Stock (SPAI), Outset Medical (OM), Modular Medical (MODD), Precision Optics (POCI), Femasys (FEMY), Spectral AI (MDAI), CollPlant Biotechnologies (CLGN), Envoy Medical (COCH), and PolyPid (PYPD). These companies are all part of the "medical equipment" industry. NeuroMetrix vs. Daxor Safe Pro Group Inc. Common Stock Outset Medical Modular Medical Precision Optics Femasys Spectral AI CollPlant Biotechnologies Envoy Medical PolyPid Daxor (NASDAQ:DXR) and NeuroMetrix (NASDAQ:NURO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Is DXR or NURO more profitable? Daxor has a net margin of 0.00% compared to NeuroMetrix's net margin of -203.71%. Daxor's return on equity of 0.00% beat NeuroMetrix's return on equity.Company Net Margins Return on Equity Return on Assets DaxorN/A N/A N/A NeuroMetrix -203.71%-42.56%-39.26% Do insiders & institutionals have more ownership in DXR or NURO? 1.3% of Daxor shares are owned by institutional investors. Comparatively, 19.4% of NeuroMetrix shares are owned by institutional investors. 59.0% of Daxor shares are owned by insiders. Comparatively, 7.3% of NeuroMetrix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend DXR or NURO? Daxor currently has a consensus target price of $25.00, indicating a potential upside of 237.38%. Given Daxor's stronger consensus rating and higher probable upside, equities analysts plainly believe Daxor is more favorable than NeuroMetrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NeuroMetrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer DXR or NURO? In the previous week, Daxor had 4 more articles in the media than NeuroMetrix. MarketBeat recorded 5 mentions for Daxor and 1 mentions for NeuroMetrix. NeuroMetrix's average media sentiment score of 1.00 beat Daxor's score of 0.20 indicating that NeuroMetrix is being referred to more favorably in the news media. Company Overall Sentiment Daxor Neutral NeuroMetrix Positive Which has preferable earnings & valuation, DXR or NURO? Daxor has higher earnings, but lower revenue than NeuroMetrix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaxor$2.13M16.82N/AN/AN/ANeuroMetrix$3.03M2.99-$6.53M-$4.59-0.96 Which has more risk and volatility, DXR or NURO? Daxor has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Does the MarketBeat Community favor DXR or NURO? NeuroMetrix received 282 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 56.69% of users gave NeuroMetrix an outperform vote. CompanyUnderperformOutperformDaxorOutperform Votes2100.00% Underperform VotesNo VotesNeuroMetrixOutperform Votes28456.69% Underperform Votes21743.31% SummaryDaxor beats NeuroMetrix on 10 of the 15 factors compared between the two stocks. Get NeuroMetrix News Delivered to You Automatically Sign up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NURO vs. The Competition Export to ExcelMetricNeuroMetrixSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.07M$4.07B$5.31B$7.35BDividend YieldN/A46.44%5.47%4.31%P/E Ratio-0.9628.0921.9417.82Price / Sales2.9947.06380.9497.68Price / CashN/A51.0838.3134.64Price / Book0.335.816.453.98Net Income-$6.53M$67.09M$3.22B$247.81M7 Day Performance0.78%1.83%5.85%3.19%1 Month Performance-3.00%-11.62%-9.58%-7.70%1 Year Performance1.71%15.43%11.85%1.49% NeuroMetrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NURONeuroMetrix1.0596 of 5 stars$4.40+1.5%N/A+1.7%$9.07M$3.03M-0.9620Short Interest ↓Positive NewsDXRDaxor4.023 of 5 stars$7.45-2.5%$25.00+235.6%-24.0%$36.04M$2.13M0.0037Short Interest ↓News CoverageGap DownSPAISafe Pro Group Inc. Common StockN/A$2.35+44.5%N/AN/A$35.65M$2.17M0.0011OMOutset Medical1.129 of 5 stars$9.58-12.0%$48.75+408.9%-68.4%$34.44M$113.69M-3.86520High Trading VolumeMODDModular Medical0.692 of 5 stars$0.80-9.1%N/A-45.5%$32.53MN/A-1.5120Short Interest ↑Negative NewsPOCIPrecision Optics0.9459 of 5 stars$4.15-1.3%N/A-28.1%$31.66M$18.68M-6.4880Short Interest ↓Positive NewsFEMYFemasys1.9296 of 5 stars$1.15-3.4%$11.50+900.0%-6.1%$31.22M$1.63M-1.4230MDAISpectral AI2.1841 of 5 stars$1.18-2.5%$4.75+302.5%-31.5%$28.13M$29.58M-1.8283Short Interest ↑Gap UpCLGNCollPlant Biotechnologies1.8551 of 5 stars$2.40-2.4%$12.50+420.8%-53.6%$27.49M$515,000.00-1.5670Positive NewsCOCHEnvoy Medical1.3053 of 5 stars$1.28-10.2%$9.00+605.9%-73.5%$25.81M$225,000.00-0.9034News CoverageGap UpPYPDPolyPid2.6161 of 5 stars$2.41-4.0%$11.33+370.3%-39.0%$24.56MN/A-0.4880Short Interest ↓Analyst RevisionNews Coverage Related Companies and Tools Related Companies Daxor Competitors Safe Pro Group Inc. Common Stock Competitors Outset Medical Competitors Modular Medical Competitors Precision Optics Competitors Femasys Competitors Spectral AI Competitors CollPlant Biotechnologies Competitors Envoy Medical Competitors PolyPid Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NURO) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroMetrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NURO Stock Free NURO Stock Alerts